| Bioactivity | (E)-5-(2-Bromovinyl)uracil (BVU) is a pyrimidine base and an inactive metabolite of the antiviral agents sorivudine and (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) that may be regenerated to BVDU in vivo. BVU irreversibly inactivates dihydropyrimidine dehydrogenase (DPD) in an NADPH-dependent manner. It enhances the efficacy of the chemotherapeutic agent and DPD substrate 5-fluorouracil (HY-90006) in a P388 murine leukemia model when administered at a dose of 200 μmol/kg, increasing survival time. |
| CAS | 69304-49-0 |
| Formula | C6H5BrN2O2 |
| Molar Mass | 217.02 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. De Clercq, et al. Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine. J. Med. Chem. 29(2), 213-217 (1986). |
(E)-5-(2-Bromovinyl)pyrimidine-2,4(1H,3H)-dione
CAS: 69304-49-0 F: C6H5BrN2O2 W: 217.02
(E)-5-(2-Bromovinyl)uracil (BVU) is a pyrimidine base and an inactive metabolite of the antiviral agents sorivudine and
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.